CSIMarket
 


Phathom Pharmaceuticals Inc   (PHAT)
Other Ticker:  
 
 

PHAT's Capital Expenditures Growth by Quarter and Year

Phathom Pharmaceuticals Inc 's Capital Expenditures results by quarter and year




PHAT Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 0.41 0.10 0.12
III Quarter September 0.94 0.13 0.01 0.18
II Quarter June 0.01 0.43 0.05 0.06
I Quarter March 0.21 0.07 0.17 0.68
FY   1.16 1.04 0.33 1.04



PHAT Capital Expenditures third quarter 2023 Y/Y Growth Comment
Phathom Pharmaceuticals Inc achieved in the third quarter 2023, above Company average Capital Expenditures surge of 622.31% year on year, to $ 0.94 millions.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 40 other companies have achieved higher Capital Expenditures growth. While Phathom Pharmaceuticals Inc ' s Capital Expenditures doubling of 622.31% ranks overall at the positon no. 776 in the third quarter 2023.




PHAT Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - 310 % -16.67 % 9.09 %
III Quarter September 622.31 % 1200 % -94.44 % 500 %
II Quarter June -97.67 % 760 % -16.67 % -
I Quarter March 200 % -58.82 % -75 % -
FY   - 215.15 % -68.27 % 642.86 %

Financial Statements
Phathom Pharmaceuticals Inc 's third quarter 2023 Capital Expenditures $ 0.94 millions PHAT's Income Statement
Phathom Pharmaceuticals Inc 's third quarter 2022 Capital Expenditures $ 0.13 millions Quarterly PHAT's Income Statement
New: More PHAT's historic Capital Expenditures Growth >>


PHAT Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - 215.38 % 900 % -33.33 %
III Quarter September 9290 % -69.77 % -80 % 200 %
II Quarter June -95.24 % 514.29 % -70.59 % -91.18 %
I Quarter March -48.78 % -30 % 41.67 % 518.18 %
FY (Year on Year)   - 215.15 % -68.27 % 642.86 %




Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #41
Healthcare Sector #112
Overall #776

Capital Expenditures Y/Y Growth Statistics
High Average Low
687.88 % 111.97 % -68.46 %
(Dec 31 2020)   (Dec 31 2021)
Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #41
Healthcare Sector #112
Overall #776
Capital Expenditures Y/Y Growth Statistics
High Average Low
687.88 % 111.97 % -68.46 %
(Dec 31 2020)   (Dec 31 2021)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Phathom Pharmaceuticals Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
15550 % 1093.77 % -97.2 %
(Sep 30 2023)  


PHAT's III. Quarter Q/Q Capital Expenditures Comment
Phathom Pharmaceuticals Inc achieved in the III. Quarter 2023 above company average sequential Capital Expenditures doubling of 9290%, to $ 0.94 millions, from $0.01 millions in the second quarter.
PHAT is undergoing a remarkable growth, not only claiming above normal gain, but also increasing rate, Nora Jansson, Major Pharmaceutical Preparations industry observer located in Boston mentioned.

Within Major Pharmaceutical Preparations industry Phathom Pharmaceuticals Inc achieved highest sequential Capital Expenditures growth. While Phathom Pharmaceuticals Inc 's Capital Expenditures growth quarter on quarter, overall rank is 9.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #1
Healthcare Sector #1
Overall #9
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #1
Healthcare Sector #1
Overall #9
Capital Expenditures Q/Q Growth Statistics
High Average Low
15550 % 1093.77 % -97.2 %
(Sep 30 2023)  


PHAT's III. Quarter Q/Q Capital Expenditures Comment
Phathom Pharmaceuticals Inc achieved in the III. Quarter 2023 above company average sequential Capital Expenditures doubling of 9290%, to $ 0.94 millions, from $0.01 millions in the second quarter.
Phathom Pharmaceuticals Inc is going from strength to strength, not just reporting better then normal gain, but also increasing speed, Nora Jansson, Major Pharmaceutical Preparations industry observer located in Boston said.

Within Major Pharmaceutical Preparations industry Phathom Pharmaceuticals Inc achieved highest sequential Capital Expenditures growth. While Phathom Pharmaceuticals Inc 's Capital Expenditures growth quarter on quarter, overall rank is 9.


Phathom Pharmaceuticals Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Capital Expenditures 12 Months Ending $ 1.57 $ 0.77 $ 1.19 $ 1.04 $ 0.73
Y / Y Capital Expenditures Growth (TTM) 115.5 % 25.78 % 425.66 % 217.38 % 107.1 %
Year on Year Capital Expenditures Growth Overall Ranking # 187 # 816 # 1915 # 2386 # 438
Seqeuential Capital Expenditures Change (TTM) 105.09 % -35.52 % 14.12 % 42.8 % 19.7 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 965 # 108 # 1735 # 1765 # 621




Cumulative Capital Expenditures growth Comment
Phathom Pharmaceuticals Inc saw improvement in Capital Expenditures growth trend, posting cumulative 12 months Capital Expenditures growth of 115.5% year on year, to $ 2 millions if the fiscal year would have ended in Sep 30 2023.
Phathom Pharmaceuticals Inc 's trailing twelve months Capital Expenditures growth was higher than company's average 111.97% and higher than 25.78% growth in Jun 30 2023.
But from twelve months ended Jun 30 2023 rise was less at 105.09 % from $0.77 millions recorded in twelve months ending a quarter before.
There is stagnation in progress, more noticeable as we look at usual sequential historic increase which is stronger at111.97%.
The growth was even more impressive from twelve months ended Jun 30 2023 showed at 105.09 % increase from $0.77 millions in twelve months ending a quarter Jun 30 2023.

In the Healthcare sector 43 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 187, from total ranking in previous quarter at 816.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
687.88 %
111.97 %
-68.46 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 50
Healthcare Sector # 44
Overall # 187

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
687.88 %
111.97 %
-68.46 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 50
Sector # 136
S&P 500 # 965
Cumulative Capital Expenditures growth Comment
Phathom Pharmaceuticals Inc saw improvement in Capital Expenditures growth trend, posting cumulative 12 months Capital Expenditures growth of 115.5% year on year, to $ 2 millions if the fiscal year would have ended in Sep 30 2023.
Phathom Pharmaceuticals Inc 's trailing twelve months Capital Expenditures growth was higher than company's average 111.97% and higher than 25.78% growth in Jun 30 2023.
But from twelve months ended Jun 30 2023 rise was beneth at 105.09 % from $0.77 millions achieved in twelve months ending a quarter before Nora Jansson added on.
We witness slowdown developing, more obvious observing the average sequential historic increase that is stronger at111.97% Nora Jansson wrote.
The growth is even stronger from the previous reporting period showed at 105.09 % jump from $0.77 millions in twelve months ending a quarter before.

In the Healthcare sector 43 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 187, from total ranking in previous quarter at 816.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
687.88 %
111.97 %
-68.46 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 50
Healthcare Sector # 44
Overall # 187

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
687.88 %
111.97 %
-68.46 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 50
Sector # 136
S&P 500 # 965




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
PHAT's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for PHAT's Competitors
Capital Expenditures Growth for Phathom Pharmaceuticals Inc 's Suppliers
Capital Expenditures Growth for PHAT's Customers

You may also want to know
PHAT's Annual Growth Rates PHAT's Profitability Ratios PHAT's Asset Turnover Ratio PHAT's Dividend Growth
PHAT's Roe PHAT's Valuation Ratios PHAT's Financial Strength Ratios PHAT's Dividend Payout Ratio
PHAT's Roa PHAT's Inventory Turnover Ratio PHAT's Growth Rates PHAT's Dividend Comparisons



Companies with similar Capital Expenditures doubling for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Sep 30 2023
Hillevax Inc 1,081.62%$ 1,081.622 millions
Aadi Bioscience Inc 976.47%$ 976.471 millions
Savara Inc 975.00%$ 975.000 millions
Arcutis Biotherapeutics Inc 966.67%$ 966.667 millions
Madrigal Pharmaceuticals Inc 927.27%$ 927.273 millions
Agios Pharmaceuticals Inc 871.05%$ 871.053 millions
Myomo Inc 843.04%$ 843.044 millions
Rocket Pharmaceuticals Inc 825.45%$ 825.447 millions
Kronos Bio Inc 787.67%$ 787.671 millions
Vaxcyte Inc 770.58%$ 770.581 millions
Minerva Surgical Inc 750.00%$ 750.000 millions
Novocure Limited748.66%$ 748.664 millions
Iteos Therapeutics Inc 694.29%$ 694.286 millions
Protalix Biotherapeutics inc 670.69%$ 670.690 millions
Procyon Corporation662.60%$ 662.602 millions
Arcus Biosciences Inc 658.73%$ 658.725 millions
Biodesix Inc 651.87%$ 651.866 millions
Eyenovia inc 646.89%$ 646.886 millions
Phathom Pharmaceuticals Inc 600.75%$ 600.746 millions
Kymera Therapeutics Inc 548.31%$ 548.315 millions
Impel Pharmaceuticals Inc 538.00%$ 538.000 millions
Enhabit Inc 533.33%$ 533.333 millions
Pacific Health Care Organization Inc 485.65%$ 485.651 millions
Biocryst Pharmaceuticals Inc 464.00%$ 464.000 millions
Axsome Therapeutics Inc 461.64%$ 461.645 millions
Nuwellis Inc 450.00%$ 450.000 millions
Biomx Inc 433.33%$ 433.333 millions
Graphite Bio Inc 426.01%$ 426.011 millions
Evelo Biosciences Inc 422.22%$ 422.222 millions
Liquidia Corporation405.32%$ 405.319 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com